{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T07:34:51Z","timestamp":1777880091572,"version":"3.51.4"},"reference-count":177,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Therapeutic Advances in Infection"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>New human immunodeficiency virus (HIV) cases related to injection drug use (IDU) in the United States increased between 2016 and 2022. The uptake of preexposure prophylaxis (PrEP) is exceedingly low in persons who inject drugs (PWID) despite its efficacy to prevent HIV. There are multilevel barriers in the PrEP care cascade for PWID. We need a combination of effective HIV prevention strategies, including PrEP, treatment for substance use disorder, and syringe services programs (SSP) to reverse the trend. A major challenge is the lack of knowledge and skills in harm reduction practices and addiction care in the infectious disease (ID) workforce. ID clinicians could benefit from education in harm reduction and addiction, including taking on the responsibility of prescribing buprenorphine or navigating the resources for it. Addiction clinicians could benefit from education on PrEP and related program implementation knowledge. Both specialties need to comprehensively evaluate and address the risks for HIV acquisition in PWID. We should create integrated clinical programs between ID and addiction. We should improve HIV screening for hospitalized PWID. We should expand low-barrier integrated clinics with flexible hours, walk-in appointments, same-day PrEP starts, and collocated laboratory and pharmacy services. Other entities that could provide integrated care include substance detoxification and rehabilitation programs, SSPs, opioid treatment programs (OTP), community pharmacies, and mobile health clinics. Long-acting injectable PrEP for PWID is an attractive option for HIV prevention, but robust implementation programs are necessary for roll-out. We still need to address upstream barriers to care for PWID, including stigma and health disparities. We need to continue to advocate for policy changes and funding for SSPs and OTPs to provide comprehensive HIV prevention.<\/jats:p>","DOI":"10.1177\/20499361251380642","type":"journal-article","created":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T11:23:04Z","timestamp":1759317784000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Integrating harm reduction and addiction care in HIV prevention among persons who inject drugs in the United States\u2014a narrative review"],"prefix":"10.1177","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-3605-8724","authenticated-orcid":false,"given":"Wei-Teng","family":"Yang","sequence":"first","affiliation":[{"name":"Division of Infectious Diseases, Department of Medicine, Perelman School of Medicine, University of Pennsylvania, 3F Silverstein, Suite E, 3400 Spruce Street, Philadelphia, PA 19104, USA"},{"name":"Center for Addiction Medicine and Policy, University of Pennsylvania, Philadelphia, PA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2025,10]]},"reference":[{"key":"e_1_3_5_2_2","unstructured":"CDC. NCHHSTP AtlasPlus https:\/\/www.cdc.gov\/nchhstp\/about\/atlasplus.html?CDC_AAref_Val=https:\/\/www.cdc.gov\/nchhstp\/atlas\/index.htm (2024 accessed 2 August 2025)."},{"key":"e_1_3_5_3_2","unstructured":"CDC. Fast facts: HIV in the United States https:\/\/www.cdc.gov\/hiv\/data-research\/facts-stats\/index.html (2024 accessed 5 November 2024)."},{"key":"e_1_3_5_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)61127-7"},{"key":"e_1_3_5_5_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-02988-x"},{"key":"e_1_3_5_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.21346"},{"key":"e_1_3_5_7_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-018-0263-5"},{"key":"e_1_3_5_8_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-021-00556-z"},{"key":"e_1_3_5_9_2","unstructured":"National Institute of Mental Health. Improving the HIV Pre-Exposure Prophylaxis (PrEP) Cascade https:\/\/www.nimh.nih.gov\/funding\/grant-writing-and-application-process\/concept-clearances\/2015\/improving-the-hiv-pre-exposure-prophylaxis-prep-cascade (2015 accessed 15 September 2024)."},{"key":"e_1_3_5_10_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae544"},{"key":"e_1_3_5_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad402"},{"key":"e_1_3_5_12_2","unstructured":"Conference on Retroviruses and Opportunistic Infections https:\/\/www.croiconference.org\/ (2025 accessed 20 April 2025)."},{"key":"e_1_3_5_13_2","unstructured":"Association for Multidisciplinary Education and Research for Substance use and Addiction https:\/\/amersa.org\/ (2025 accessed 20 April 2025)."},{"key":"e_1_3_5_14_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1511480"},{"key":"e_1_3_5_15_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-017-0196-4"},{"key":"e_1_3_5_16_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp2103274"},{"issue":"7","key":"e_1_3_5_17_2","article-title":"How should harm reduction be included in care continua for patients with opioid use disorder?","volume":"26","author":"Salisbury-Afshar E","year":"2024","unstructured":"Salisbury-Afshar E, Livingston CJ, Bluthenthal RN. How should harm reduction be included in care continua for patients with opioid use disorder? AMA J Ethics 2024; 26(7): E562\u2013E571.","journal-title":"AMA J Ethics"},{"key":"e_1_3_5_18_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12902-023-01529-6"},{"key":"e_1_3_5_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pmedr.2016.05.012"},{"key":"e_1_3_5_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2020.106099"},{"key":"e_1_3_5_21_2","unstructured":"National Institute for Health and Care Excellence. Tobacco: preventing uptake promoting quitting and treating dependence https:\/\/www.nice.org.uk\/guidance\/ng209\/chapter\/Recommendations-on-treating-tobacco-dependence#supporting-people-who-do-not-want-or-are-not-ready-to-stop-smoking-in-one-go-to-reduce-their-harm (2021 accessed 4 November 2024)."},{"key":"e_1_3_5_22_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2006.tb00209.x"},{"key":"e_1_3_5_23_2","doi-asserted-by":"publisher","DOI":"10.1177\/1559827620905775"},{"key":"e_1_3_5_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001039"},{"key":"e_1_3_5_25_2","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.51716"},{"key":"e_1_3_5_26_2","doi-asserted-by":"publisher","DOI":"10.1080\/713659379"},{"key":"e_1_3_5_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(05)66475-6"},{"key":"e_1_3_5_28_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)62353-7"},{"key":"e_1_3_5_29_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.42228"},{"key":"e_1_3_5_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11524-023-00717-y"},{"issue":"5","key":"e_1_3_5_31_2","article-title":"NYC\u2019s overdose prevention centers: data from the first year of supervised consumption services","volume":"5","author":"McAteer JM","year":"2024","unstructured":"McAteer JM, Mantha S, Gibson B, et al. NYC\u2019s overdose prevention centers: data from the first year of supervised consumption services. NEJM Catalyst Innov Care Deliv 2024; 5(5).","journal-title":"NEJM Catalyst Innov Care Deliv"},{"key":"e_1_3_5_32_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.e5945"},{"key":"e_1_3_5_33_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2014.03.006"},{"key":"e_1_3_5_34_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000000165"},{"key":"e_1_3_5_35_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.20622"},{"key":"e_1_3_5_36_2","unstructured":"Substance abuse and mental health services administration. Notice of proposed rulemaking to update 42 CFR Part 8: medications for the treatment of opioid use disorder https:\/\/public-inspection.federalregister.gov\/2022-27193.pdf (2022 accessed 12 November 2024)."},{"key":"e_1_3_5_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-021-00535-y"},{"key":"e_1_3_5_38_2","unstructured":"Federal register. Medications for the treatment of opioid use disorder: removal of the DATA-2000 Waiver Requirements https:\/\/www.federalregister.gov\/documents\/2023\/02\/13\/2023-03012\/medications-for-the-treatment-of-opioid-use-disorder-removal-of-the-data-2000-waiver-requirements (2023 accessed 12 November 2024)."},{"key":"e_1_3_5_39_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.25999"},{"key":"e_1_3_5_40_2","doi-asserted-by":"publisher","DOI":"10.3122\/jabfm.2023.230048R1"},{"key":"e_1_3_5_41_2","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.90a.23022"},{"key":"e_1_3_5_42_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001202"},{"key":"e_1_3_5_43_2","unstructured":"WHO. Evidence for action technical papers: effectiveness of sterile needle and syringe programming in reducing HIV\/AIDS among injection drug users. Geneva Switzerland WHO 2004."},{"key":"e_1_3_5_44_2","unstructured":"Javed Z Burk K Facente S et al. Syringe services programs: a technical package of effective strategies and approaches for planning design and implementation. Atlanta GA US Department of Health and Human Services National Center for HIV\/AIDS Viral Hepatitis STD and TB Prevention Center for Disease Control and Prevention 2020."},{"key":"e_1_3_5_45_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyt243"},{"key":"e_1_3_5_46_2","volume-title":"National Ryan While Conference on HIV Care & Treatment","author":"Hinojosa C.","year":"2022","unstructured":"Hinojosa C. Assessing need for primary care services at a needle exchange program: safe recovery. In: National Ryan While Conference on HIV Care & Treatment. Virtual presentation; 2022."},{"key":"e_1_3_5_47_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109540"},{"key":"e_1_3_5_48_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2015.1011820"},{"key":"e_1_3_5_49_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2018.1443541"},{"key":"e_1_3_5_50_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-023-00394-x"},{"key":"e_1_3_5_51_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa2212412"},{"key":"e_1_3_5_52_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109107"},{"key":"e_1_3_5_53_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2020.3711"},{"key":"e_1_3_5_54_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2559"},{"key":"e_1_3_5_55_2","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2018.1546862"},{"key":"e_1_3_5_56_2","doi-asserted-by":"publisher","DOI":"10.1111\/add.13479"},{"key":"e_1_3_5_57_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11414-018-9586-y"},{"key":"e_1_3_5_58_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm7325a1"},{"key":"e_1_3_5_59_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1901276"},{"key":"e_1_3_5_60_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-023-00868-w"},{"key":"e_1_3_5_61_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix333"},{"issue":"1","key":"e_1_3_5_62_2","article-title":"How structural violence, prohibition, and stigma have paralyzed North American responses to opioid overdose","volume":"22","author":"Tyndall M","year":"2020","unstructured":"Tyndall M, Dodd Z. How structural violence, prohibition, and stigma have paralyzed North American responses to opioid overdose. AMA J Ethics 2020; 22(1): E723\u2013E728.","journal-title":"AMA J Ethics"},{"key":"e_1_3_5_63_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001104"},{"issue":"1","key":"e_1_3_5_64_2","article-title":"Recent modifications to the US methadone treatment system are a band-aid-not a solution-to the nation's broken opioid use disorder treatment system","volume":"1","author":"Krawczyk N","year":"2023","unstructured":"Krawczyk N, Joudrey PJ, Simon R, et al. Recent modifications to the US methadone treatment system are a band-aid-not a solution-to the nation's broken opioid use disorder treatment system. Health Aff Sch 2023; 1(1): qxad018.","journal-title":"Health Aff Sch"},{"key":"e_1_3_5_65_2","article-title":"Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system","volume":"2020","author":"Madras BK","year":"2020","unstructured":"Madras BK, Ahmad NJ, Wen J, et al. Improving access to evidence-based medical treatment for opioid use disorder: strategies to address key barriers within the treatment system. NAM Perspect 2020; 2020.","journal-title":"NAM Perspect"},{"key":"e_1_3_5_66_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2021.306665"},{"key":"e_1_3_5_67_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2005.01232.x"},{"key":"e_1_3_5_68_2","doi-asserted-by":"publisher","DOI":"10.1080\/10550880903183042"},{"key":"e_1_3_5_69_2","article-title":"Predictors of retention and drug use among patients with opioid use disorder transferred to a specialty \u201cSecond Chance\u201d methadone program","volume":"16","author":"Moses TE","year":"2022","unstructured":"Moses TE, Rhodes GL, Tavakoli E, et al. Predictors of retention and drug use among patients with opioid use disorder transferred to a specialty \u201cSecond Chance\u201d methadone program. Subst Abuse 2022; 16.","journal-title":"Subst Abuse"},{"key":"e_1_3_5_70_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.11.1000"},{"key":"e_1_3_5_71_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amepre.2021.05.044"},{"key":"e_1_3_5_72_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2020.06.013"},{"key":"e_1_3_5_73_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1515195"},{"key":"e_1_3_5_74_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000001098"},{"key":"e_1_3_5_75_2","doi-asserted-by":"publisher","DOI":"10.1001\/journalofethics.2016.18.3.hlaw1-1603"},{"key":"e_1_3_5_76_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2019.305268"},{"key":"e_1_3_5_77_2","doi-asserted-by":"publisher","DOI":"10.1177\/0033354920921817"},{"key":"e_1_3_5_78_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-023-08183-7"},{"key":"e_1_3_5_79_2","doi-asserted-by":"publisher","DOI":"10.1080\/14659891.2022.2144500"},{"key":"e_1_3_5_80_2","volume-title":"Recommended best practices for effective syringe exchange programs in the United States: results of a consensus meeting","author":"Bluthenthal RN","year":"2009","unstructured":"Bluthenthal RN, Clear A, Des Jarlais DC, et al. Recommended best practices for effective syringe exchange programs in the United States: results of a consensus meeting. New York, NY: New York City Department of Health and Mental Hygiene, 2009."},{"key":"e_1_3_5_81_2","unstructured":"CDC. Understanding the Opioid Overdose Epidemic https:\/\/www.cdc.gov\/overdose-prevention\/about\/understanding-the-opioid-overdose-epidemic.html (2024 accessed 5 November 2024)."},{"key":"e_1_3_5_82_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2019.01.010"},{"key":"e_1_3_5_83_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2019.305366"},{"key":"e_1_3_5_84_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa128"},{"key":"e_1_3_5_85_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiaa112"},{"key":"e_1_3_5_86_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002673"},{"key":"e_1_3_5_87_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.35857"},{"key":"e_1_3_5_88_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.35895"},{"key":"e_1_3_5_89_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2020.06.007"},{"key":"e_1_3_5_90_2","unstructured":"Harm Reduction International. Brief paper: harm reduction for stimulant use https:\/\/www.hri.global\/files\/2019\/04\/28\/harm-reduction-stimulants-coact.pdf (2019 accessed 13 November 2024)."},{"key":"e_1_3_5_91_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.pbb.2015.03.023"},{"key":"e_1_3_5_92_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.abrep.2021.100398"},{"key":"e_1_3_5_93_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-024-01038-2"},{"key":"e_1_3_5_94_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000001299"},{"key":"e_1_3_5_95_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-024-00478-2"},{"key":"e_1_3_5_96_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-023-00729-6"},{"key":"e_1_3_5_97_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-020-06201-6"},{"key":"e_1_3_5_98_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2020.108058"},{"key":"e_1_3_5_99_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2024.111133"},{"key":"e_1_3_5_100_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae450"},{"key":"e_1_3_5_101_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-023-15429-w"},{"key":"e_1_3_5_102_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-023-04060-w"},{"key":"e_1_3_5_103_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S315543"},{"key":"e_1_3_5_104_2","doi-asserted-by":"publisher","DOI":"10.2196\/13015"},{"key":"e_1_3_5_105_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab658"},{"key":"e_1_3_5_106_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000002558"},{"key":"e_1_3_5_107_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12981-019-0248-9"},{"key":"e_1_3_5_108_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2022.107037"},{"key":"e_1_3_5_109_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-071688"},{"key":"e_1_3_5_110_2","unstructured":"Roth AM. NCT05192434: trauma intervention to optimize PrEP among women who inject drugs (TIARAS) https:\/\/clinicaltrials.gov\/study\/NCT05192434?cond=NCT05192434&rank=1#study-plan (2024 accessed 8 November 2024)."},{"key":"e_1_3_5_111_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2019.06.012"},{"key":"e_1_3_5_112_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-022-00706-5"},{"key":"e_1_3_5_113_2","volume-title":"Conference on Retroviruses and Opportunistic Infections","author":"Gillespie G","year":"2024","unstructured":"Gillespie G, Carstens RP, Zang X, et al. Safety and pharmacokinetics of MK-8527, a novel nRTTI, in adults without HIV. In: Conference on Retroviruses and Opportunistic Infections, Denver, USA, 2024."},{"issue":"81","key":"e_1_3_5_114_2","article-title":"HIV pre-exposure prophylaxis programmatic preferences among people who inject drugs: findings from a discrete choice experiment","volume":"19","author":"Eger WH","year":"2024","unstructured":"Eger WH, Bazzi AR, Valasek CJ, et al. HIV pre-exposure prophylaxis programmatic preferences among people who inject drugs: findings from a discrete choice experiment. Addict Sci Clin Pract 2024; 19(81).","journal-title":"Addict Sci Clin Pract"},{"key":"e_1_3_5_115_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-024-00447-9"},{"key":"e_1_3_5_116_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2019.0235"},{"key":"e_1_3_5_117_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2021.306208"},{"key":"e_1_3_5_118_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-022-00721-6"},{"key":"e_1_3_5_119_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000973"},{"key":"e_1_3_5_120_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11904-023-00667-9"},{"key":"e_1_3_5_121_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciae531"},{"key":"e_1_3_5_122_2","unstructured":"Clinicaltrial.gov. Study of Lenacapavir and Emtricitabine\/Tenofovir Disoproxil Fumarate (F\/\u2009TDF) for Prevention of HIV in People Who Inject Drugs (HPTN 103) (PURPOSE 4) https:\/\/clinicaltrials.gov\/study\/NCT06101342 (2024 accessed 10 November 2024)."},{"key":"e_1_3_5_123_2","unstructured":"AVAC. PrEPWatch: Products https:\/\/www.prepwatch.org\/products\/ (2024 accessed 10 November 2024)."},{"key":"e_1_3_5_124_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe2408591"},{"key":"e_1_3_5_125_2","doi-asserted-by":"publisher","DOI":"10.1097\/QAI.0000000000003370"},{"key":"e_1_3_5_126_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae640"},{"key":"e_1_3_5_127_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2402088"},{"key":"e_1_3_5_128_2","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25351"},{"key":"e_1_3_5_129_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1810743"},{"key":"e_1_3_5_130_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11908-019-0685-6"},{"key":"e_1_3_5_131_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-020-02800-w"},{"key":"e_1_3_5_132_2","doi-asserted-by":"publisher","DOI":"10.15585\/mmwr.mm6446a4"},{"key":"e_1_3_5_133_2","unstructured":"CDC. Preexposure prophylaxis for the prevention of HIV infection in the United States\u20142021 Update: a clinical practice guideline https:\/\/stacks.cdc.gov\/view\/cdc\/112360 (2021 accessed 26 September 2025)."},{"key":"e_1_3_5_134_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.mcna.2021.09.002"},{"key":"e_1_3_5_135_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000801"},{"key":"e_1_3_5_136_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab631"},{"key":"e_1_3_5_137_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0217811"},{"key":"e_1_3_5_138_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2014.02.005"},{"key":"e_1_3_5_139_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-022-00689-3"},{"key":"e_1_3_5_140_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-022-00642-4"},{"key":"e_1_3_5_141_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-009-9576-4"},{"key":"e_1_3_5_142_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2017.02.007"},{"key":"e_1_3_5_143_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2005.12.007"},{"key":"e_1_3_5_144_2","unstructured":"CDC. HIV infection risk prevention and testing behaviors among persons who inject drugs\u2014national HIV behavioral surveillance 20 U.S. Cities 2022. HIV Surveillance Special Report 35. February 2024 https:\/\/www.cdc.gov\/hiv\/library\/reports\/hiv-surveillance.html (2024 accessed 9 November 2024)."},{"key":"e_1_3_5_145_2","doi-asserted-by":"publisher","DOI":"10.1080\/10826084.2022.2083171"},{"key":"e_1_3_5_146_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab633"},{"key":"e_1_3_5_147_2","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2021.1993326"},{"key":"e_1_3_5_148_2","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2015-133720"},{"key":"e_1_3_5_149_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000123"},{"key":"e_1_3_5_150_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idc.2020.06.015"},{"key":"e_1_3_5_151_2","doi-asserted-by":"publisher","DOI":"10.1097\/ADM.0000000000000991"},{"key":"e_1_3_5_152_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-024-00502-5"},{"key":"e_1_3_5_153_2","unstructured":"Boston Medical Center. Combined Infectious Disease and Addiction Medicine Fellowship https:\/\/www.bumc.bu.edu\/care\/education-and-training-programs\/care-program-fellowship-in-addiction-medicine\/curriculum\/combined-infectious-disease-and-addiction-medicine-fellowship\/#:~:text=Boston%20Medical%20Center%20hosts%20the Infectious%20Disease%20and%20Addiction%20Medicine (2024 accessed 6 November 2024)."},{"key":"e_1_3_5_154_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz804"},{"key":"e_1_3_5_155_2","doi-asserted-by":"publisher","DOI":"10.3389\/frph.2021.684717"},{"key":"e_1_3_5_156_2","doi-asserted-by":"publisher","DOI":"10.1071\/SH18062"},{"key":"e_1_3_5_157_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2015.1129388"},{"key":"e_1_3_5_158_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2024.209539"},{"key":"e_1_3_5_159_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.japh.2022.09.003"},{"key":"e_1_3_5_160_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac670"},{"key":"e_1_3_5_161_2","doi-asserted-by":"publisher","DOI":"10.1080\/08897077.2019.1675118"},{"key":"e_1_3_5_162_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-024-00451-z"},{"key":"e_1_3_5_163_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofae204"},{"key":"e_1_3_5_164_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciad202"},{"key":"e_1_3_5_165_2","doi-asserted-by":"publisher","DOI":"10.1089\/apc.2023.0061"},{"key":"e_1_3_5_166_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13722-023-00365-2"},{"key":"e_1_3_5_167_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-021-03220-0"},{"key":"e_1_3_5_168_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-022-06085-3"},{"key":"e_1_3_5_169_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12954-024-00983-2"},{"key":"e_1_3_5_170_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiz673"},{"key":"e_1_3_5_171_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10461-024-04366-3"},{"key":"e_1_3_5_172_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13063-023-07899-5"},{"key":"e_1_3_5_173_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07354-x"},{"key":"e_1_3_5_174_2","volume-title":"Conference of Retroviruses and Opportunistic Infections","author":"Andrew P","year":"2025","unstructured":"Andrew P, El-Bassel N, Shoptaw S, et al. Preliminary efficacy for HPTN 094: 26-week RCT of integrated strategies for people who inject drugs. In: Conference of Retroviruses and Opportunistic Infections, San Francisco, CA, USA, 2025."},{"key":"e_1_3_5_175_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2023.104214"},{"key":"e_1_3_5_176_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.josat.2023.209160"},{"key":"e_1_3_5_177_2","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0b013e32834f5cf2"},{"key":"e_1_3_5_178_2","unstructured":"Brody J. HIV program response to Boston HIV cluster: data trends 2019-2023 https:\/\/www.bhchp.org\/blog\/2019-2023-hiv-outcomes-at-bhchp\/ (2023 accessed 13 September 2024)."}],"container-title":["Therapeutic Advances in Infectious Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361251380642","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/20499361251380642","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/20499361251380642","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:01:48Z","timestamp":1777593708000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/20499361251380642"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":177,"alternative-id":["10.1177\/20499361251380642"],"URL":"https:\/\/doi.org\/10.1177\/20499361251380642","relation":{},"ISSN":["2049-9361","2049-937X"],"issn-type":[{"value":"2049-9361","type":"print"},{"value":"2049-937X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7]]},"article-number":"20499361251380642"}}